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Abstract
Introduction: The long-term course of rheumatoid arthritis (RA) in terms of health status is not well understood,
nor is the degree of effectiveness of biologic therapy in the community. We modeled the progression of loss of
health status, and measured incremental costs and effectiveness of biologic therapy in the community.
Methods: We studied change in function and health status in 18,485 RA patients (135,731 observations) at six-
month intervals for up to 11 years, including a group of 4,911 patients (59,630 observations) who switched to
biologic therapy from non-biologic therapy. We measured the SF-36 Physical Component (PCS) and Mental
Component (MCS) Summary scales, the EQ-5D health utility scale, and the Health Assessment Questionnaire (HAQ)
disability scale; and we calculated treatment and direct medical costs.
Results: RA onset caused an immediate and substantial reduction in physical but not mental health status.
Thereafter, the progression of dysfunction in RA was very slow (HAQ 0.016 units and PCS -0.125 units annually),
only slightly worse than the age and sex-adjusted US population. We estimated biologic treatment to improve
HAQ by 0.29 units, PCS by 5.3 units, and EQ-5D by 0.05 units over a 10-year period. The estimated incremental 10-
year total direct medical cost for this benefit was $159,140.
Conclusions: Biologic therapy retards RA progression, but its effect is far less than is seen in clinical trials. In the
community, cost-effectiveness is substantially less than that estimated from clinical trial data. The study results
represent the incremental benefit of adding biologic therapy to optimum non-biologic therapy.
Introduction
Biologic therapy for rheumatoid arthritis (RA) has been
shown to be efficacious in multiple clinical trials [1-10].
This efficacy extends from composite measures that
include physician, patient, and laboratory tests such as
the Disease Activity Index-28 (DAS28) [11] and the
American College of Rheumatology (ACR) improvement
criteria [12], to imaging studies [1], as well as to purely
patient-based assessments such as the Health Assess-
ment Questionnaire disability index (HAQ) and the
Short Form-36 (SF-36) [13]. Efficacy data, from these
trials, usually based on the HAQ or health utility scales
[14], are used in cost-effectiveness studies and
assessments of costs per Quality Adjusted Life-Years
(QALYs) [15], and extrapolated to future but unob-
served results.
The degree of effectiveness of biologic therapy treat-
ments in clinical practice in the community, however,
has not been established, but effectiveness studies often
show less benefit than efficacy studies. The idea of effec-
tiveness (Does it work in the community?) is somewhat
different from the idea of efficacy (Does it work in the
clinical trial setting?). In addition, effectiveness implies
sustained improvement in generally unselected popula-
tions (Does it really work?), and effectiveness studies are
concerned with the degree of improvement and, some-
times, with the cost of improvement, areas that we
investigate in the current study.
With respect to RA treatment, there is another impor-
tant difference between community effectiveness studies
and randomized clinical trials. In the community,
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already being used. Thus, observed benefit from biologic
therapy in the community represents the incremental
benefit of adding biologic therapy. Observational studies
do not represent an alternative to the experimentation
of randomized clinical trials, but rather represent a set
of complementary approaches, as the external validity,
or generalizability,o ft h er e s u l t so fr a n d o m i z e dt r i a l si s
often low [16,17].
Health status and functional status are central compo-
nents of RA outcomes. They are meaningful to patients
and form the basis of cost-effectiveness pronouncements
[14]. In addition, because it is almost impossible to
carry out large, long-term, population-based studies that
include imaging and reliable physician assessments,
effectiveness studies in RA are more easily executed
using patient assessments that measure health-related
quality of life and function.
As background to the question of biological therapy
effectiveness in RA, we first describe the lifetime course
of health status in RA and then the 10-year observed
course of health status in RA patients in order to pro-
vide information about RA and to provide further vali-
dation for the study methods. We then examine the
incremental benefit of biologic therapy in an unselected
population of patients with RA by following patients
longitudinally who switch from non-biologic treatment
of at least six months duration to biologic treatment
during their ordinary clinical care. Thus, patients pro-
vide their own controls. We assess patients continuously
in both periods using semiannual mailed and web-based
questionnaires, using PCS, MCS, HAQ, and EQ-5D as
the study outcome measures. We calculate the rates of
progression of loss of health status in both treatment
periods, and we compare the rates to determine treat-
ment effect, adjusting for important socio-economic dif-
ferences; we also determine direct treatment and total
medical costs. Essentially, the question we ask is, ‘What
is the effect of biologic therapy on the functional and
health status of patients starting this therapy compared
with their previous course?’
Materials and methods
We studied 18,485 adult patients with RA who partici-
pated in the National Data Bank for Rheumatic Diseases
(NDB) longitudinal study of RA outcomes. Participants
are volunteers, recruited from the practices of US rheu-
matologists, who complete mailed or Internet question-
naires about their health at six-month intervals. They
are not compensated for their participation. The diagno-
s i so fR Ai sm a d eb yt h ep a t i e n t ’s rheumatologist.
Patients who were recruited to participate in the NDB
as they started a biologic therapy, specifically as part of
a biologic safety registry, were excluded from this study
because of the possibility of severity bias. The NDB uti-
l i z e sa no p e nc o h o r td e s i g ni nw h i c hp a t i e n t sa r e
enrolled continuously.
Patients were assessed on a semiannual basis between
1998 and 2009. At each assessment we obtained treat-
ment and demographic data by patient self-report.
Patients were considered to be on biologic therapy if
they used any of the following treatments during the
time of the study: etanercept, infliximab, adalimumab,
abatacept, certolizumab pegol, or rituximab. For the
study health status and function measures, we calculated
the physical (PCS) and mental (MCS) component sum-
mary scores from the SF-36 version 1 according to the
authors’ recommendations [18,19]. The primary time
period of the SF-36 questionnaire was four weeks. We
used the EQ-5D to determine health utilities. The EQ-
5D is a five-item questionnaire that assesses function
(three questions), mood (one question) and pain (one
question) [20]. Scoring was accomplished using US tar-
iffs (weights) [21,22]. US and European scores are not
interchangeable, with US scores being approximately
0.11 units greater [23]. To measure functional status, we
used the Health Assessment Questionnaire disability
index (HAQ) [24]. The HAQ has 34 questions, includ-
ing 20 activities of daily living items and 14 aids and
devices. The SF-36, EQ-5D, and the HAQ have been
used extensively in RA research. To compare study
patients with age and sex matched patients in the US
population (Figure 1) we used published normative data
for the PCS and MCS [25] and EQ-5D [21].
We computed a comorbidity score based on the pre-
sence of pulmonary disorders, myocardial infarction,
other cardiovascular disorders, stroke, hypertension, dia-
betes, spine/hip/leg fracture, depression, GI ulcer, other
GI disorders, and cancer, as previously described [26].
Direct medical costs, adjusted to 2007, were deter-
mined from semi-annual hospitalization, treatment and
utilization data, and applied using US Centers for Medi-
care and Medicaid Services fee schedules for procedures,
and average wholesale prices for treatments, for the cor-
responding year, as previously reported [27].
Statistical methods
As the course of RA may extend to more than 60 years,
no study can encompass the duration of the illness, and
many of the study instruments we used have been in
common use for less than 25 years [28,29]. To partially
overcome this problem in describing the course of RA
(Figure 1 and Table 1), we used an accelerated cohort
design [30]. In this design the time metric is the duration
of RA, not the semi-annual wave of study assessments. A
potential problem with accelerated cohort design studies
is data sparseness. However, there were sufficient
patients in this study to avoid this problem: 605 patients
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long duration longitudinal studies using this design, right
censoring may be a problem in that the patients with the
longest RA duration may be survivors and differ systema-
tically from non-participants (non-survivors). We used
the accelerated cohort design in order to be able to
describe long duration RA health status. Readers may
choose to examine graphic data at maximum durations
of 30 or 40 years to avoid problems that might be caused
by this censoring. In addition, 1,514 patients had RA for
≤2 years and 4,174 for ≤4 years when first enrolled in the
NDB. The major part of the study (Tables 2 and 3, Figure
2), which deals with observed time rather than duration
of RA, utilized semi-annual cohort assessments over a
maximum of 11 years.
Missing data
Missing data occurred through two mechanisms in this
study: 1) when patients did not complete or validly com-
plete a questionnaire item (mechanism 1) and 2) when the
item was not part of the assessment questionnaire
(mechanism 2). The NDB made use of three types of ques-
tionnaires. All participants completed at least once a com-
prehensive 28-page questionnaire that included all study
questions. Over the course of the study the comprehensive
questionnaire was completed at 92.7% of observations, and
had missing data rates for HAQ, PCS, and MCS of 0.4%,
3.2%, and 3.2%, respectively (mechanism 1). A short ques-
tionnaire and an even shorter (brief) questionnaire were
completed by 6.5% and 1.0% of patients. These question-
naires did not include the PCS, MCS, HAQ, EQ-5D, or
Figure 1 The change in health status over the lifetime course of RA. The change in health status over the lifetime course of 18,485 RA
patients for PCS (upper left), MCS (upper right), EQ-5D (lower left), and HAQ (lower right). The dashed lines for PCS, MCS, and EQ-5D represent
age and sex adjusted population normative data. See methods for details. HAQ, Health Assessment Questionnaire; PCS, SF-36 Physical
Component Summary; MCS, SF-36 Mental Component Summary.
Table 1 Annualized lifetime rates of progression and levels of disability and health status in rheumatoid arthritis
Variable All patients
(N = 18,485)
Rate of progression
Rate (95% CI)
Values at RA duration
Of 0 years (onset)*
Mean (95% CI)
Values at RA duration
of 10 years*
Mean (95% CI)
Values at RA duration
of 20 years
Mean (95% CI)
HAQ 0.016 (0.015, 0.017) 0.84 (0.83, 0.86) 1.00 (0.99, 1.01) 1.16 (1.15, 1.18)
PCS -0.125 (-0.142, -0.108) 37.9 (37.6, 38.1) 36.6 (36.5, 36.8) 35.4 (35.2, 35.6)
MCS 0.047 (0.031, 0.063) 48.5 (48.3, 48.8) 49.0 (48.8, 49.1) 49.4 (49.4, 49.6)
EQ-5D -0.001 (-0.001, -0.000) 0.748 (0.742, 0.754) 0.739 (0.736, 0.743) 0.731 (0.727, 0.735)
Positive rates indicate worsening HAQ disability. Negative rates indicate worsening health status for MCS, PCS, and EQ-5D. Values at 0, 10, and 20 years RA
duration are estimated from the mixed model regression analysis.
HAQ, Health Assessment Questionnaire; PCS, SF-36 Physical Component Summary; MCS, SF-36 Mental Component Summary.
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shorter questions are older and have lower health status
compared with patients completing the comprehensive
questionnaire. Considering all questionnaires, the overall
missing data rate for HAQ, PCS, and MCS was 8.1%,
10.8%, and 10.8%, respectively. The missing data rate for
total household income (comprehensive questionnaire)
was 4.2% (mechanism 1). Because of the possibility that
excluding data from short and brief questions would intro-
duce unacceptable bias, we elected to impute the missing
variables. To replace missing values, we used multiple
imputation by chained equations (ICE) to create five mul-
tiple imputed datasets for analyses [31], and we combined
data according to Rubin’s rules [32]. The EQ-5D was not
Table 2 Annualized observed rates of progression of disability and loss of health status in rheumatoid arthritis
Variable All patients
(N = 18,485)
Rate (95% CI)
Biologics never used
(N = 10,265)
Rate (95% CI)
Biologics ever used
(N = 8,220)
Rate (95% CI)
HAQ 0.013 (0.010, 0.015) 0.016 (0.013, 0.019) 0.010 (0.007, 0.013)
PCS 0.035 (0.001, 0.069) -0.003 (-0.048, 0.041) 0.068 (0.022, 0.114)
MCS 0.039 (0.008, 0.069) 0.001 (-0.041, 0.063) 0.044 (-0.003, 0.090)
EQ-5D 0.001 (0.001, 0.002) -0.000 (-0.001, 0.001) 0.002 (0.012, 0.003)
Annualized observed rates of progression of disability and loss of health status in 18,485 RA patients during up to 10 years of observation.
Positive rates indicate worsening HAQ disability. Negative rates indicate worsening health status for MCS, PCS, and EQ-5D.
HAQ, Health Assessment Questionnaire; PCS, SF-36 Physical Component Summary; MCS, SF-36 Mental Component Summary.
Table 3 Effect of biologic therapy on rheumatoid arthritis progression
Variable N Pre biologic therapy
Rate (95% CI)
Post biologic therapy
Rate (95% CI)
Rate difference
Rate (95% CI)
HAQ (all) 4,911 0.032 (0.027, 0.036) 0.003 (0.000, 0.006) -0.029 (-0.023, -0.034)
HAQ (on) 3,829 0.031 (0.026, 0.036) -0.001 (-0.004, 0.002) -0.033 (-0.026, -0.039)
HAQ (DC) 1,082 0.033 (0.021, 0.044) 0.013 (0.008, 0.017) 0.020 (0.007, 0.033)
PCS (all) 4,911 -0.353 (-0.432, -0.273) 0.179 (0.129, 0.229) -0.532 (-0.634, -0.430)
PCS (on) 3,829 -0.348 (-0.436, -0.260) 0.261 (0.198, 0.323) -0.608 (-0.725, -0.491)
PCS (DC) 1,082 -0.396 (-0.591, -0.201) -0.003 (-0.082, 0.075) -0.393 (-0.619, -0.166)
MCS (all) 4,911 -0.096 (-0.176, -0.016) 0.000 (-0.056, 0.057) -0.096 (-0.197, 0.005)
MCS (on) 3,829 -0.124 (-0.211, -0.037) 0.052 (-0.012, 0.116) -0.176 (-0.289, -0.063)
MCS (DC) 1,082 0.015 (-0.083, 0.212) -0.117 (-0.226, -0.008) 0.132 (-0.104, 0.368)
EQ-5D (all) 3,997 -0.003 (-0.005, -0.000) 0.002 (0.001, 0.003) -0.005 (-0.008, -0.002)
EQ-5D (on) 3,031 -0.003 (-0.006, 0.000) 0.003 (0.002, 0.004) -0.006 (-0.009, -0.002)
EQ-5D (DC) 966 -0.001 (-0.007, 0.004) -0.001 (-0.003, 0.002) -0.001 (-0.007, 0.006)
All patients Pre biologic therapy
Mean (95% CI)
Post biologic therapy
Mean (95% CI)
Cost difference
Mean (95% CI)
Total Costs 4,911 $8,454 (8,140, 8,769) $24,369 (21,172, 24,565) $15,914 (15,543, 16,285)
Drug Costs 4,911 $4,681 (4,401, 4,961) $20,401 (20,226, 20,576) $15,720 (15,390, 16,051)
Variable N Estimated scores
Time = -10 years
Mean (95% CI)
Actual scores
Time = 0 years
Mean (95% CI)
Estimated scores
Time = +10 years
Mean (95% CI)
HAQ 4,911 1.02 (0.99, 1.05) 1.13 (1.11, 1.15) 1.24 (1.21, 1.27)
PCS 4,911 35.2 (34.7, 35.6) 35.4 (35.1, 25.7) 35.7 (35.2, 36.1)
MCS 4,911 50.2 (49.8, 50.7) 49.8 (49.5, 50.1) 49.3 (48.9, 49.8)
EQ-5D 3,997 0.721 (0.709, 0.733) 0.730 (0.724, 0.736) 0.740 (0.730, 0.749)
Effect of biologic therapy on annual rates of progression of disability, loss of health status, and costs in patients prior to and after the start of biologic therapy in RA.
All, all patients; on, on biologics at study close; DC, discontinued biologic before study close.
Positive rates indicate worsening HAQ disability. Negative rates indicate worsening health status for MCS, PCS, and EQ-5D. A negative rate difference indicates
improvement. Times are relative to biologic therapy initiation.
HAQ, Health Assessment Questionnaire; PCS, SF-36 Physical Component Summary; MCS, SF-36 Mental Component Summary.
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values were missing for that reason. We elected to not
impute missing data for the EQ-5D.
Specific analyses
In the main analyses we used a two-level mixed
model with the individual patient as the second level
and, depending on the analysis, different duration
variables as the random intercept and random slope.
In the RA duration model (Table 1 and Figure 1),
the fixed covariates were age at RA onset and sex. In
the observed duration model (time in the NDB)
(Tables 2 and 3, Figure 2), the fixed effect covariates
included: comorbidity, sex, year of RA onset, age at
first NDB participation, education level, sex, and
total household income. In the treatment model,
duration was calculated as time before and time after
treatment, with a range. In this model the fixed cov-
ariates were the same as in the observed duration
model.
In all of these analyses, we first explored a series of
different functional forms for time (duration of RA,
duration in study, duration on treatment) and deter-
m i n e dt h a tn o n - l i n e a rt e r m soffered no advantage over
linear terms. In addition, we conducted sensitivity ana-
lyses using fully imputed data, singly imputed data, and
case-deletion. We did not find substantial differences in
results, and we report multiple imputed data unless spe-
cifically indicated.
In Figure 1 the HAQ, PCS, MCS, and EQ-5D lines,
and in Figure 2 the HAQ and PCS lines, were based on
predictions from the mixed model, using the fixed-por-
tion linear predictor plus contributions based on pre-
dicted random effects. The predictions were smoothed
using kernel-weighted local polynomial regression. The
distribution curves at the y-axis of Figure 2 represent
the distribution at treatment time 0, and were calculated
by kernel density estimates.
For ease of interpretation of Table 3 data, estimated
p r e d i c t e dv a l u e so fH A Q ,P C S ,M C Sa n dE Q - 5 Da r e
presented at time points of -10 and +10 years, based on
adjusted regression analyses.
Validation dataset
To understand if the annual rate of change in the out-
c o m ev a r i a b l e sr e p o r t e di nt h i ss t u d yw a sc o n s i s t e n t
with clinical practice, we obtained a second dataset of
Health Assessment Questionnaire (HAQ-II) data from
847 RA patients seen during ordinary care in a five-
rheumatologist clinical practice. The HAQ-II is a 10-
item questionnaire that was based on the HAQ. Its
scores are essentially the same as those of HAQ. The
Pearson correlation coefficient between the HAQ and
HAQ-II is 0.85, and Lin’s concordance coefficient is
0.85 [33]. The difference between HAQ and HAQ-II
mean is 0.01 units.
We also used this data set to develop an algorithm for
estimating DAS28 scores from linear regression analysis
Figure 2 Changes in HAQ and PCS in patients treated with biologic therapy. Changes in HAQ and PCS in patients who started a biologic
therapy at time 0. Horizontal graphs at y-axis represent curves of the distribution of values for HAQ (above) and PCS (below) at time 0. Annual
cost is the annual cost calculated for the 10-year duration before and the 10-year duration after the start of biologic therapy. HAQ, Health
Assessment Questionnaire; PCS, SF-36 Physical Component Summary; MCS, SF-36 Mental Component Summary.
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the validity of standard errors was not an issue, we used
all 3,450 observations from the 847 RA patients. The R-
square of the model was 0.39. The algorithm was: Esti-
mated DAS28 = 1.877544 + (HAQ-II * 0.1382091) +
(VAS pain * 0.0849938) + (VAS patient global *
0.2230887). Substituting the HAQ for the HAQ-II, we
calculated an estimated DAS28 in the NDB dataset.
This is a rough estimate, and should only be used for
putting the NDB data into perspective.
A l ld a t aw e r ea n a l y z e du s i n gS t a t a1 1 . 0( S t a t aC o r -
poration, College Station, TX, USA). Statistical signifi-
cance was set at the 0.05 level.
The study was carried out in compliance with the Hel-
sinki Declaration, and was approved by the Institutional
Review Board of the St. Francis Regional Medical Cen-
ter, Wichita, KS, USA. All patients signed an informed
consent.
Results
At entry into the NDB, the median duration of RA for
study participants was 9.7 years and the mean HAQ
(1.1), PCS (35.8), and EQ-5D (0.73) scores were abnor-
mal, particularly in comparison with age- and sex-
matched persons in the general population for PCS and
E Q - 5 D ,a ss h o w ni nT a b l e4 .M C Ss c o r e s ,h o w e v e r ,
were similar in RA and the general population. In addi-
tion, the standard deviations and inter-quartile ranges of
these four study measures were large, indicating hetero-
geneity of health status in RA. Methotrexate (MTX) and
biologics were used by 60.8% and 44.5% of participants
over the duration of the study. The lifetime exposure to
disease modifying anti-rheumatic drugs (DMARDs) was
92.3%, and to triple therapy (methotrexate + sulfasala-
zine + hydroxychloroquine) was 3.7%.
How does health status change over time?
Figure 1 displays the average course of health status in RA
patients over a period of 60 years (solid line). The long-
dashed line represents expected values based on normative
age and sex adjusted data from the general US population,
except for HAQ where normative data are not available.
The four scales demonstrate that, on average, profound
loss of health status occurs immediately at the onset of
Table 4 Characteristics of 18,485 patients with rheumatoid arthritis at study entry unless otherwise specified
Variable Patient Data Community Norms
Mean (SD) IQR Range Mean (SD) Range
HAQ 1.06 (0.73) 1.00 (0.50 to 1.62) 0.00 to 3.00
PCS 35.8 (11.0) 34.7 (27.3 to 44.1) 6.5 to 69.4 46.2 (3.4) 40.2 to 55.3
MCS 49.0 (11.3) 51.4 (40.7 to 58.0) 7.6 to 75.2 50.8 (1.46) 45.0 to 52.7
EQ-5D 0.73 (0.19) 0.78 (0.69 to 0.83) -0.11 to 1.00 0.83 (0.03) 0.79 to 0.93
Age (years) 59.9 (13.0)
Sex (% male) 23.3
Non-Hispanic White (%) 89.8
High school graduate (%) 89.4
College graduate (%) 26.3
Income (median $US) 35,000
RA duration (median IQR) years 9.7 (4.4 to 18.1)
Study duration (years) 3.7 (3.2) 0.5 to 11.0
Study duration biologic comparison) (years) 6.1 (3.0) 1.0 to 11.0
Comorbid conditions (none) (%) 27.2
Comorbid conditions (1) (%) 27.1
Comorbid conditions (≥ 2) (%) 45.8
Satisfied or very satisfied with health (%) 51.5
MTX (%) 47.8
MTX (anytime in study) (%) 60.8
Prednisone (%) 40.5
Biologic (anytime in study) (%) 44.5
DMARD use (lifetime) (%) 92.3
Triple therapy (lifetime) (%) 3.7
HAQ, Health Assessment Questionnaire; PCS, SF-36 Physical Component Summary; MCS, SF-36 Mental Component Summary; RA, rheumatoid arthritis; MTX,
methotrexate; DMARD, Disease-Modifying Anti-Rheumatic Drug; triple therapy, methotrexate (MTX) + hydroxychloroquine (HCQ) + sulfasalazine (SSZ).
Community norms are age and sex-adjusted to the NDB study population.
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the three scales with physical predominance (PCS, EQ-
5D, HAQ), there is a generally linear loss of health status
over the next 60 years. However, the rate of loss is only
slightly increased compared with the loss of health status
that is associated with aging in the general population.
There is no increase in the rate of loss of health status
over time compared with the general population as mea-
sured by the MCS. Indeed the MCS in RA is indistin-
guishable from population normative data. No
population normative data are available for the HAQ, but
its pattern of loss is similar to that of PCS and EQ-5D.
These data can be summed up as follows: on average,
loss of health status occurs immediately, at the onset of
RA, and most of the further deterioration in health status
that occurs is the deterioration expected by aging inde-
pendent of RA duration. MCS is an exception to the gen-
eral observation of loss of health status over time. Mental
health generally improves slightly over time, and hardly
differs from population values.
While the three PCS, EQ-5D, and HAQ graphs show
substantial loss of health status over 60 years, the actual
mean annual loss is very small, virtually imperceptible.
Table 1 and Figure 1 provide information about the rate
of progression of RA over the lifetime of the illness.
From its intercept, the HAQ increases by 0.016 units
per year, the PCS by 0.125 units, and the EQ-5D by
0.001 units per year. It is important to recognize that
Figure 1 speaks to the average course of RA. However,
the standard deviations and interquartile range (IQR)
for all of the measures in Figure 1 are quite wide. For
example, as shown in Table 4, the interquartile range
( I Q R )o ft h eH A Qi s0 . 5 0t o1 . 6 2 5a n dt h eI Q Ro ft h e
PCS is 27.3 to 44.1. This large dispersion is also shown
well in the distribution curves at time zero for the HAQ
and PCS in Figure 2.
What is the contemporary rate of change in health status
in RA?
We examined the rate of change in health status in detail
during the 11-year period of NDB observations (1998 to
2009), using the time metric of time in study (11 years),
and adjusting for age, comorbidity, year of RA onset, sex,
education, and household income (Table 2). During this
time, very slight changes in health status were observed.
HAQ scores worsened, and PCS, MCS, and EQ-5D
scores improved. The annual increase (worsening) in
HAQ score was 0.013 (95% CI 0.010, 0.015) units, which
is equivalent to a 10-year change of 0.13 units. The
annualized improvement rates were PCS 0.035 (95% CI
0.001, 0.069), MCS 0.039 (95% CI 0.008, 0.069), and EQ-
5D 0.001 (95% CI 0.001, 0.002). These improvement
rates are so small that they can be considered to repre-
sent a stable or no-change condition.
When only patients never treated with biologics were
considered (Table 2) HAQ scores worsened by 0.016
per year (95% CI 0.013, 0.019), but no significant
changes were seen for PCS, MCS, or EQ-5D. Finally, we
examined patients who had received biologics during
their period of observation in the NDB. The HAQ wor-
sened by 0.010 units per year (95% CI 0.007, 0.013),
PCS improved by 0.068 (95% CI 0.022, 0.114) units per
year, MCS improved by 0.044 (95% CI -0.003, 0.090),
and EQ-5D improved by 0.002 (95% CI 0.012, 0.003)
units per year. These data also suggest that patients who
received biologics had a course that was more favorable
than those not treated with these agents.
What is the effect of biologic therapy and its cost?
To assess the effect of biologic therapy, we determined
annual rates of progression up to the time of receipt of
biologic therapy and the rates following administration of
such therapy in patients who switched to a biologic while
being followed in the NDB. These data are shown graphi-
cally in Figure 2 and in detail in Table 3. The mean dura-
tion of time on biologics from time 0 was 3.6 years,
(median (IQR) 2.8 (1.0 to 5.8) years) during a mean fol-
low-up from time 0 of 4.3 (3.8 (1.5 to 6.5)) years). The
DAS28 estimated score immediately prior to biologic
start was 3.2, with 41.2% having estimated scores <3.2
and 18.9% have estimated DAS28 scores ≥5.1.
At study closure, 78.8% of patients who started biologics
were still receiving them. The annualized rate differences,
or benefit for biologic treatment compared to non-biologic
treatment, were for HAQ, -0.029 (95% CI -0.023, -0.034),
for PCS, -0.532 (95% CI -0.634, -0.430), for MCS, -0.096
(95% CI -0.197, 0.005), and for EQ-5D, -0.005 (95% CI
-0.008, -0.002). As is suggested by the rates, the scores at
times -10, 0, and +10 years for the combined treatment
group differed only slightly (Table 3). In addition, the dis-
tribution plots at the y-axis of Figure 2 show that there
was wide variability in scores in patients who received bio-
logics. Overall, the effect of biological therapy, while easily
discernible, was slight.
We further examined the course of patients who
s t a r t e db i o l o g i c sa n dr e m a i n e do n( o n )t h e ma sw e l la s
patients who discontinued biologics (DC), as shown in
Table 3. As might be expected, patients who started and
remained on biologic treatment throughout the study
had a more favorable course. For example, they had a
mean HAQ score reduction of 0.033 units compared
with a decrease of 0.020 units for those discontinuing
therapy.
We determined the direct treatment costs and direct
total medical costs for each year prior to and after treat-
ment start. Table 3 presents the annualized costs
adjusted to 2007 US dollars; and these costs are
summed in Figure 2 and estimated for the 10 years
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Page 7 of 12before and the 10 years after treatment start. The
annualized treatment costs for all patients post-biologic
start was $20,401 (95% CI 20,226, 20,576) and the total
cost was $24,369 (95% CI 21,172, 24,565). Compared
with pretreatment years, annualized treatment costs
were $15,720 (95% CI 15,390, 16,051) and total costs
were $15,914 (95% CI 15,543, 16,285) greater in biologic
treated patients.
Are the results similar to the progression rates in the
clinic: external validation of HAQ progression?
To understand whether the rates of progression were
similar in the NDB surveys and the clinic, we calculated
the annual rate of HAQ-II increase from 847 RA
patients with 6,444 observations during ordinary care in
a five-rheumatologist clinical practice (Arthritis and
Rheumatology Clinics of Kansas (ARCK)). Each patient
had at least one year of follow-up and three clinic visits.
The median (IQR) duration of RA at study start was
10.1 (2.9 to 13.0) years. At the last observation, the
mean (standard deviation (SD)) age of patients was 60.6
(13.4) years, the HAQ-II was 1.0 (SD), pain was 4.4
(2.6), the DAS28 score was 3.15 (SD), and 57.3% of
patients were satisfied or very satisfied with their health.
The mean ESR was 20.9 mm/hr, and there were 2.0
swollen and 2.0 tender joint, using the 28 joint count
method of the DAS28. Fifty-nine percent used biologics
during the study period. Only the HAQ-II was available
because the PCS, MCS, and EQ-5D are not ordinarily
obtained in clinical practice. The annualized rate of
HAQ-II progression was 0.018 (95% CI 0.001, 0.036)
units per year, a rate similar to the overall progression
rate of 0.013 obtained in the current study (Table 2),
though slightly higher, perhaps reflecting the difference
between survey and clinic patients.
Discussion
There are several major findings from this study with
respect to RA in general. First, the onset of RA causes,
on average, an immediate and substantial reduction in
health status, as measured by HAQ, PCS, and EQ-5D
scores (Figure 1). Second, after onset, the progression of
dysfunction in treated RA is very slow. Third, the
further decrement in health status over time is only
slightly greater than that in the general population, dif-
fering primarily by the initial differences between RA
and those without RA. Fourth, the variance in any
health status measure, at any moment in time, is large
as shown in Table 4 and Figure 2.
But perhaps the most important finding of this study
was the limited effect of biologic therapy on measures
of health status and function. We did find that biologic
therapy altered the rate of decrement in health status as
measured by the differences in the pretreatment and
post-treatment rates of progression. When this effect is
expressed in terms of a more manageable 10-year effect
rather than a 1-year effect, it can be seen that the esti-
mated 10-year improvement following biologic therapy
w a s0 . 2 9u n i t sf o rt h eH A Q ,5 . 3u n i t sf o rt h eP C S ,a n d
0.05 units for the EQ-5D. These values slightly exceed
the levels considered to represent minimal clinically
important change for these variables [34,35], but are
almost six times less than the biologic treatment effect
on HAQ identified in a recent meta-analysis comparing
methotrexate with biologi c si nR Ao fl e s st h a nt h r e e
years duration [36]. We also found that the estimated
annual increase in total medical and total treatment
costs for the second 10-year period compared with the
first was close to $16,000.
By contrast, randomized clinical trials of biologics
almost universally find changes that we identified over
10 years as occurring over the course of the 6- or 12-
month clinical trial [1]. When clinical trial results are
extrapolated in cost-effectiveness analyses, it is pre-
sumed that the 6- to 12-month improvement will con-
tinue for most patients, and that patients who fail to
i m p r o v ew i l ld i s c o n t i n u et h e r a p y[ 3 7 , 3 8 ] .T h ed e g r e eo f
improvement found in clinical trials as well as the pre-
sumption of continued improvement lead to cost per
QALY estimates between $40,000 to $68,000 for biolo-
gic therapies [15,37,39,40]. Although we did not do for-
mal cost-effectiveness analyses, our data suggest cost-
per-QALY (or incremental cost-effectiveness ratio) may
be 5 to 10 times more than calculated in models based
on trials.
Patients in the community differed in other ways from
patients in clinical trials. Not only did our patients not
do as well as those in clinical trials, they also started
therapy with much better health status, a mean HAQ
score of 1.1 (Table 3) and an estimated DAS28 score of
3.2, and they generally did not discontinue biologics for
lack of meeting HAQ improvement criteria (HAQ
improvement ≥0.25). Using the DAS28 estimation algo-
rithm derived from ARCK data, we estimate that 41.2%
of our patients starting biologics already had DAS28
scores of <3.2 at the time they started a biologic; 18.9%
were estimated to have DAS28 scores ≥5 . 1a tt h a tt i m e
point, an indicator of high disease activity.
We believe that the results of our study can be under-
stood as representing the incremental benefit of biologic
therapy when it is added to close to optimum non-bio-
logic therapy, therapy that can include DMARDs,
NSAIDs, and systemic and intra-articular corticoster-
oids. Patients in our study were treated by rheumatolo-
gists and had received DMARD therapy prior to starting
biologics. So we may presume that they received con-
temporary, specialist, and perhaps close-to-optimum
therapy.
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Page 8 of 12A recent study from Moreland et al. sheds light on the
incremental benefit in efficacious combination therapies
and strategies [41]. They compared the response of 755
methotrexate (MTX) naïve patients with very active RA
(mean DAS28 = 5.8) and an RA duration of less than or
equal to three years who were treated in a randomized
clinical trial with immediate vs. step-up strategy with
MTX, etanercept and triple DMARD in four arms:
immediate MTX + etanercept or triple therapy; step-up
from MTX to MTX+ etanercept or to triple therapy.
Patients on combination therapy improved most by six
months of treatment, but after two years, there was no
significant difference between the groups in outcome
measures, and the DAS28 at study closure was 3.0 [41].
Data such as these suggest that improvement can be
expected when biologics are added to patients being
appropriately treated with DMARDS, but that such
improvement is limited.
The Moreland et al. study is particularly relevant
because its add-on etanercept treatment arm is similar
to the add-on therapy received in our study as part of
ordinary clinical care. Based on a conversion algorithm,
we estimated that patients in our study had DAS28
scores of approximately 3.2 at biologic start. In addition,
in the 721 patients in the ARCK validation dataset the
measured DAS-28 score was 3.3 (SD 1.3). Thus the
mean DAS28 scores in treated RA may range, approxi-
mately, from values around 3.0 in the aggressively trea-
ted Moreland et al. study, to 3.3 in the clinical patients
in the community, and to 3.2 estimated in the NDB sur-
veys. These observations add support to the idea that
there is a general, average level of disease activity that
occurs in the presence of contemporary RA treatment.
In a similarly relevant study, Ma et al. performed a
meta-analysis of treatments in patients with less than
three years of RA (15 studies, 4,200 patients), comparing
MTX monotherapy with combination DMARDs and
with combined DMARD-biologic therapy [36]. At entry,
the DAS score was high (4.3 to 6.2). HAQ improvement
in the combined DMARD group was -0.17 (95% CI
-0.33, -0.01) units and vs. the DMARD/biologic group
was -0.16 (-0.26, -0.04) units compared with methotrex-
ate monotherapy. As with the Moreland et al. study
[41], they found no benefit with combination therapy
compared with methotrexate plus biologics.
An additional example of additive treatment response
comes from the SWEFOT (Swedish Pharmacotherapy)
trial where 487 patients with RA of less than one year
were treated with methotrexate for three to four months
[42]. A favorable response (DAS28 ≤3.2) was noted in
145. Of 258 without a favorable response, 130 were
allotted randomly to triple therapy DMARD therapy and
128 to infliximab. Twenty-five percent of patients allo-
cated sulfasalazine and hydroxychloroquine achieved the
primary outcome compared with 39% assigned inflixi-
mab. At entry the HAQ score was 1.3, but final scores
were not reported. Thus, these data also suggest that
biologic therapy conveys a small incremental benefit to
monotherapy and combination DMARD therapy.
It is of interest that although triple therapy has been
f o u n dt ob ee f f e c t i v ei nt h ea b o v es t u d i e s ,o n l y3 . 7 %o f
patients in our study had ever used triple therapy. In
addition, the median duration of RA at the inception of
our study was 9.7 years, so we could not specifically
address the recommendation of the American College of
Rheumatology (ACR) that biologics combined with
MTX should be the initial therapy for active early RA
[43]. However, our results, small incremental benefit
from biologics, are more in line with the recommenda-
tions of NICE (National Institute for Health and Clinical
Excellence) in the United Kingdom (UK) that suggest
treating early RA first with DMARD therapy [44].
The NICE report also addresses mild or less active
RA, indicating that ‘all trials of DMARDs have had
active disease as an inclusion criterion ... Studies [are]
needed to determine whether it would be safe/effective
for people with mild disease to be observed over time
without DMARD therapy, or with monotherapy, unless
their disease becomes more aggressive. It may be that
combination therapies are not appropriate for all people
with mild RA.’
Biologic therapy in the US is approved for use in
moderate or severe RA, often interpreted as use in
those with treatment failure. But the definition of treat-
ment failure is flexible, and dependent on cost, availabil-
ity, expectations, and satisfaction with health status, in
addition to physician and laboratory measurements. Fol-
lowing NICE severity guidelines, the 7,083 biologic-trea-
ted patients in the British Society of Rheumatology
Biologic Registry (BSRBR) had very active RA at biolo-
gic start [45]. Their mean HAQ score was 2.1 compared
with 1.1 in the NDB, the UK EQ-5D 0.30 vs. 0.73 (EQ-
5D US), and the DAS28 6.7 vs. 3.2 (estimated). For the
patients described in Table 4, 9.3% had HAQ scores
≥2.0, 9.2% had EQ-5D UK scores ≤0.3, and <1% had an
estimated DAS28 score ≥6.7. Thus the patients in our
current study, who are generally representative of RA in
the community in the US including those who received
biologic therapy, are systematically different from
patients in the BSRBR and, generally, from participants
in randomized clinical trials. While we applaud the ele-
gant studies of Brennan et al. [45] and others in
patients with active RA, it is not clear that their results
can be extrapolated to the population of biologic users
in the US, including those who appear to continue bio-
l o g i ct h e r a p yd e s p i t et h ea b s e n c eo fm o d e r a t eo rg o o d
European League Against Rheumatism (EULAR)
response [45].
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nature of and the rate of progression of loss of health
status. Regardless of whether we measured health status
with the HAQ, PCS or EQ-5D, we found that health sta-
tus was lost very early in the course of RA. This is not
surprising because pain is the greatest contributor to
global health status. What may be surprising, however,
is that on average 84% of the HAQ score at 10 years
and >95% of the PCS score change occurs immediately
around the onset of RA (Table 1). These findings com-
port with the slow rate of loss of health status that we
noted. We found the yearly HAQ progression rate to be
0.016 (0.015, 0.017) over the duration of RA, with an
intercept of 0.84. The one-year rate in the ARCK clinical
group was 0.018 (0.001, 0.036), and in the patients in
Table 3 was 0.032 (0.27, 0.36) in biologic treated
patients prior to biologic start and 0.003 (0.000, 0.006)
following the start of therapy. It seems possible that the
slow rate of progression we noted after RA onset may
be due to increasingly effective therapy with methotrex-
ate and other biologic and non-biologic DMARDs.
Our study approached RA and treatment outcomes in
a manner different from that of clinical trials. The main
outcome of clinical trials is usually comparative
improvement, while the main interest in longitudinal
outcome studies is the level of health status. In addition,
instead of DAS scores or ACR improvement criteria
[12] in patients with active RA in clinical trials, we
examined the effect of RA and its treatment on health
status in average patients in the US community. While
we were unable to measure RA activity, we measured
the consequence of RA activity and RA treatment with
the HAQ and SF-36, widely accepted, validated tools
that effectively predict important RA outcomes, such as
mortality, work disability, household income, and other
patient outcomes [46-49]. These measures incorporate
RA activity, in particular RA pain, with cumulative RA
effect and damage. Bansback et al. indicate that that the
HAQ is the ‘primary clinical measure for use in eco-
nomic evaluations as it is measured in almost all clinical
studies, and is closely correlated to health utilities, mor-
tality and costs.’ [14]
It is often not recognized that low levels of disease
activity (DAS28 scores of approximately 3.0 to 3.2) do
not mean no activity. But, as the ARCK data show, at a
DAS28 score of 3.15, the average RA patient had a
HAQ-II score of 1.0, VAS pain score of 4.4, and two
swollen and two tender joints; 42.7% patients were not
satisfied with their health. In the current NDB study, we
found profound impairment in PCS, HAQ, and EQ-5D
despite a low estimated DAS28 score.
There are a number of advantages to the methods of
our study. Because patients and their physicians decide
when to start and stop therapy without regard to trial
needs, external validity is high. Indeed, the finding that
the average patient starting therapy was much less
severe than in clinical trials speaks to increased general-
izability. One advantage of the method used in our
study is that it measures long-term treatment effects,
and is not sensitive to flares and flare/response changes.
As observational studies can be sensitive to regression
to the mean [50], change in slopes within patients pro-
vides protection against that bias.
T h e r ea r ean u m b e ro fl i m i t a t i o n st ot h i ss t u d y .W e
relied on self-report of start and stop dates of treatment,
and these dates might be reported inaccurately to us. To
account for this potential problem we performed sensi-
tivity analyses under a series of assumptions, including
calculations using a pre-treatment start time six months
earlier. We did not observe differences in results. Even
so, it is possible that some attenuation of effect of biolo-
gic therapy might have occurred because of our methods.
Another point that should be considered is that impli-
cit in the rate change data in the biologic treatment
group are two assumptions that cannot be tested; first,
that the increased rate of progression noted in the pre-
treatment group would have continued had they not
been treated; second that the treatment received
resulted in the change in progression rate. While these
assumptions seem reasonable, they represent counterfac-
tuals that cannot be tested.
Patients in our study had more education, and higher
levels of household income than seen in the general
population. In addition, minorities were under-repre-
sented in this study. These are characteristics of survey
participants [51]. Because we had measures of these
socio-demographic covariates, we adjusted for them in
our analyses, and it is unlikely these study characteristics
altered the results of our study. Finally, we were con-
cerned that data from clinic patients and survey patients
might be different because of the difference in setting.
However, we were assured by noting that the rate for
progression of HAQ disability was similar in the ARCK
clinic as in the surveys.
A final limitation of this study is that it represents
only US data. There are no strict standards for biologic
use in the US. Patients in this study with mild RA
received biologics, a use that would be considered inap-
propriate in many other countries, given the cost of
these therapies.
T h ed a t ao ft h i ss t u d yr a i s ean u m b e ro fo t h e rq u e s -
tions about health status in RA and its measurement.
RA results in progressive damage to joints, a fact that is
verified by radiographic damage and joint replacements
that may become necessary later in the course of the ill-
ness. From observations such as these, one may come to
the reasonable conclusion that there is a progressive
loss function and health status. The problem with this
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Page 10 of 12interpretation is not that it is necessarily wrong, but that
it doesn’t, on average, comport with the results of vali-
dated health status measures that show that the pro-
found loss of health status occurs very early in RA. Our
data suggest that there might be a substantial disconnect
between damage and health status, and that pain and
difficulty and uncertainty, the burden of RA, may impact
measured self-reported health status more than damage.
Conclusions
RA onset caused an immediate and substantial reduc-
tion in physical but not mental health status. Thereafter,
the progression of dysfunction in RA was very slow
(HAQ 0.016 units and PCS -0.125 units annually, only
slightly worse than the age and sex-adjusted US popula-
tion. We estimated biologic treatment to improve HAQ
by 0.29 units, PCS by 5.3 units, and EQ-5D by 0.05
units over a 10-year period. The estimated incremental
10-year total direct medical cost for this benefit was
$159,140. Biologic therapy retards RA progression, but
its effect is far less in the community than is seen in
clinical trials. Consequently, cost-effectiveness is sub-
stantially less than that estimated from clinical trial data.
The study results represent the incremental benefit of
adding biologic therapy to optimum non-biologic ther-
apy, and are in accord with recent add-on studies.
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